We are live on ! Find out more
AEGR

Aegerion Pharmaceuticals
AEGR

Delisted

AEGR was delisted on the 29th of November, 2016.

Back to rankings

109 hedge funds and large institutions have $1.18B invested in Aegerion Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

81% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 16

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

37% more call options, than puts

Call options by funds: $15.7M | Put options by funds: $11.5M

14% more capital invested

Capital invested by funds: $1.03B → $1.18B (+$147M)

14% more funds holding

Funds holding: 96 → 109 (+13)

Holders
109
Holders Change
+13
Holders Change %
+13.54%
% of All Funds
2.86%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
29
Increased
36
Reduced
25
Closed
16
Calls
$15.7M
Puts
$11.5M
Net Calls
+$4.2M
Net Calls Change
+$5.33M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$14.5M
2
BC
Broadfin Capital
New York
+$14.3M
3
State Street
State Street
Massachusetts
+$5.1M
4
OAM
Oxford Asset Management
United Kingdom
+$4.89M
5
BIM
Bogle Investment Management
Massachusetts
+$3.99M

Top Sellers

Rank Fund Capital Flow
1
NTC
North Tide Capital
Massachusetts
-$12.5M
2
PI
Putnam Investments
Massachusetts
-$5.88M
3
GTC
Ghost Tree Capital
New York
-$3.4M
4
Morgan Stanley
Morgan Stanley
New York
-$3.08M
5
CS
Credit Suisse
Switzerland
-$3.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Americafirst Capital Management
California
$844M +$459K +38,097 +84%
SCM
2
Scopia Capital Management
New York
$57.6M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$43.2M – – –
BC
4
Broadfin Capital
New York
$35.5M +$14.3M +1,189,925 +51%
SCM
5
Sarissa Capital Management
Connecticut
$26.1M +$301K +25,000 +1%
Vanguard Group
6
Vanguard Group
Pennsylvania
$19.9M +$1.05M +86,965 +5%
BFA
7
BlackRock Fund Advisors
California
$16.5M +$1.44M +119,669 +8%
Millennium Management
8
Millennium Management
New York
$15.6M +$1.62M +134,966 +10%
PI
9
Putnam Investments
Massachusetts
$14.4M -$5.88M -488,300 -26%
AC
10
Armistice Capital
New York
$12.1M +$14.5M +1,202,000 New
Morgan Stanley
11
Morgan Stanley
New York
$8.46M -$3.08M -255,927 -23%
BIT
12
BlackRock Institutional Trust
California
$7.73M +$148K +12,300 +2%
ACA
13
Avoro Capital Advisors
New York
$7.41M -$881K -73,175 -9%
OAM
14
Oxford Asset Management
United Kingdom
$5.93M +$4.89M +406,297 +236%
State Street
15
State Street
Massachusetts
$4.28M +$5.1M +423,858 New
SIM
16
Spark Investment Management
New York
$3.9M +$3.87M +321,800 +497%
TC
17
TFS Capital
Pennsylvania
$3.78M +$2.28M +189,644 +103%
BIM
18
Bogle Investment Management
Massachusetts
$3.35M +$3.99M +331,717 New
Northern Trust
19
Northern Trust
Illinois
$3.29M +$64.5K +5,361 +2%
Charles Schwab
20
Charles Schwab
California
$3.09M +$1.57M +130,622 +74%
HS
21
HighVista Strategies
Massachusetts
$2.56M -$146K -12,100 -5%
AC
22
Amici Capital
New York
$2.46M +$2.93M +243,700 New
JG
23
Jefferies Group
New York
$2.25M +$2.68M +222,500 New
CS
24
Credit Suisse
Switzerland
$1.93M -$3.05M -253,703 -57%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$1.77M +$17.8K +1,477 +0.9%
1
2 3 4 5

AEGR Hedge Fund Activity: Q4 2015 in Review

109 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q4 2015, worth a combined $1.18B — up 14% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new AEGR positions and 16 closed out — a net gain of 13 holders — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $14.5M. The largest seller was North Tide Capital, exiting entirely with an estimated $12.5M sold.

  • 109 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q4 2015, up from 96 in Q3 2015.
  • Funds reported $1.18B of Aegerion Pharmaceuticals stock for Q4 2015, up 14% quarter-over-quarter.
  • 29 funds opened new Aegerion Pharmaceuticals positions in Q4 2015 and 16 closed out, a net change of +13 holders.
  • The largest Aegerion Pharmaceuticals buyer in Q4 2015 was Armistice Capital, an estimated $14.5M added.
  • The largest Aegerion Pharmaceuticals seller in Q4 2015 was North Tide Capital, an estimated $12.5M sold.

Based on aggregated 13F filings for Q4 2015.